COBALT advised venture capital funds Creathor Venture and MTIP (MedTech Innovation Partners) in financing the Finnish startup Blueprint Genetics.
Blueprint Genetics is an internationally successful provider of clinical genetic testing for the diagnosis of inherited diseases.
The start-up will receive a total of up to € 14 million from the financing round, which was led by new investors, while existing investors Inventure and Pontos Group were participating as well.
We advised clients throughout the transaction, including due diligence and negotiation of transaction documents.
Clients were advised by COBALT Partner Kristel Raidla-Talur and Associates Greete-Kristiine Kuru, Jesse Kivisaari, Aleksander Tsuiman and Liina Saaremets.